None listed
Conditions
Brief summary
Community acquired pneumonia is a common cause of hospital admission and can be life-threatening. Despite effective antibiotics, some patients develop complications, need intensive care, or die. Vitamin C is a natural antioxidant important for immune function and healing. Patients who require hospitalisation with infections like pneumonia often have low vitamin C levels. Giving vitamin C may help recovery, but this has not been tested in a large clinical trial in pneumonia. The purpose of this study is to determine whether vitamin C supplementation improves outcomes in patients hospitalised with pneumonia. We believe that Vitamin C supplementation in people who have pneumonia will lead to improvement in outcomes. We will be studying if the use of Vitamin C will reduce the time to recovery, affect length of hospital stay and improve post-discharge quality of life.
Interventions
This study will investigate the effect of oral sodium ascorbate (vitamin C) supplementation compared with placebo in patients hospitalised with community-acquired pneumonia (CAP). Participants will be randomly assigned to receive either vitamin C or a matching placebo, in
addition to standard pneumonia care (e.g., antibiotics, oxygen therapy, and supportive
treatment as clinically indicated). The intervention arm will be will be Vitamin C in a sodium ascorbate formulation 1 g three times daily f
This study will investigate the effect of oral sodium ascorbate (vitamin C) supplementation compared with placebo in patients hospitalised with community-acquired pneumonia (CAP). Participants will be randomly assigned to receive either vitamin C or a matching placebo, in addition to standard pneumonia care (e.g., antibiotics, oxygen therapy, and supportive treatment as clinically indicated). The intervention arm will be will be Vitamin C in a sodium ascorbate formulation 1 g three times daily for 7 days, followed by 500 mg twice daily for one month. The Vitamin C will be administered as an oral tablet and adherence to the intervention will be monitored through phone call at the 30-day and 6-month mark by asking patient whether they have been taking the trial medication regularly as prescribed and how often doses are missed.
Sponsors
Southern Adelaide Local Health Network
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults aged greater than or equal to 18 years. 2. Hospitalised with community-acquired pneumonia (CAP), defined by clinical symptoms (cough, sputum production, dyspnoea, fever) and imaging evidence of pulmonary infiltrate.
Exclusion criteria
1. Hospital admission >48 hours before screening. 2. Inability of patient or substitute decision maker to provide informed consent. 3. Pneumonia not the principal reason for admission. 4. Dysphagia or inability to take oral medications. 5. Bronchiectasis or suspected tuberculosis. 6. Hospital admission within the past 2 weeks. 7. Severe immunosuppression (e.g., neutropenia <350 cells/µL, hematologic malignancy, HIV with CD4+ 20 mg/day, anti-rejection medications). 8. History of nephrolithiasis. 9. Renal impairment (eGFR <30 mL/min). 10. Glucose-6-phosphate dehydrogenase (G6PD) deficiency. 11. Haemochromatosis. 12. Pregnancy or breastfeeding. 13. Concurrent enrollment in another clinical trial where co-enrollment is not allowed. 14. Expected death or withdrawal of life-sustaining measures within 48 hours.
Outcome results
None listed